Personalized Uterine Fibroid Treatment Platform
Legal Citation
Summary of the Inventive Concept
A next-generation platform for treating uterine fibroids, integrating real-time monitoring, personalized medicine, and advanced tissue breakdown techniques to provide more effective and minimally invasive treatments.
Background and Problem Solved
The original patent's treatment method using purified collagenase has limitations in terms of efficacy, dosage, and delivery. The new inventive concept addresses these limitations by incorporating cutting-edge technologies such as wearable devices, genetic profiling, high-frequency ultrasound, and machine learning algorithms to provide a more comprehensive and targeted approach to uterine fibroid treatment.
Detailed Description of the Inventive Concept
The platform consists of a wearable device that administers a customized dose of collagenase to the fibroid tissue based on real-time ultrasound monitoring of fibroid size and shape. Additionally, a patient's genetic profile is analyzed to determine the optimal dosage and formulation of collagenase for maximum efficacy. The platform also includes a composition comprising a combination of collagenase and a fibroblast growth factor inhibitor to enhance the degradation of collagen and reduce fibroid growth. Furthermore, a minimally invasive probe delivers a high-frequency ultrasound pulse to the fibroid tissue, followed by administration of collagenase to enhance tissue breakdown. A computer-implemented system predicts the likelihood of uterine fibroid recurrence, based on machine learning algorithms that analyze a patient's medical history, genetic profile, and fibroid characteristics.
Novelty and Inventive Step
The new claims introduce a paradigm shift in uterine fibroid treatment by integrating wearable devices, genetic profiling, high-frequency ultrasound, and machine learning algorithms, which are not present in the original patent. The inventive concept's novelty lies in its ability to provide personalized, real-time, and minimally invasive treatments, which are not achievable with the original patent's method.
Alternative Embodiments and Variations
Alternative embodiments of the platform could include the use of different types of wearable devices, such as implantable sensors or smart patches. Variations of the composition could include different ratios of collagenase and fibroblast growth factor inhibitor or the addition of other therapeutic agents. The platform could also be adapted for treating other types of fibroids or tumors.
Potential Commercial Applications and Market
The personalized uterine fibroid treatment platform has significant commercial potential in the medical device and pharmaceutical industries, particularly in the areas of women's health and oncology. The platform's ability to provide more effective and minimally invasive treatments could lead to increased adoption and market share, as well as potential partnerships with healthcare providers and insurance companies.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K9/48 |
| A | A61 | A61K9/0019 |
| A | A61 | A61K9/0034 |
| A | A61 | A61K9/1075 |
| A | A61 | A61K38/43 |
| A | A61 | A61K38/4886 |
| A | A61 | A61K45/06 |
| C | C12 | C12Y304/24003 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical device technologies and biotechnology, specifically focused on minimally invasive treatment methods for soft tissue disorders, with expertise in collagenase-based interventions, ultrasound imaging, and personalized medical technologies
Person of Ordinary Skill (PHOSITA) Profile
A medical device engineer or biomedical researcher with advanced degrees in bioengineering, medical technology, or related fields, possessing knowledge of tissue engineering, medical imaging, drug delivery systems, and personalized medicine techniques
Obviousness Rationale
A PHOSITA would recognize that the PTD's variations represent predictable extensions of the source patent's core methodology by integrating known technologies in personalized medicine, medical imaging, and targeted drug delivery. The fundamental approach of administering collagenase to uterine fibroids remains consistent, with the PTD introducing incremental technological enhancements that would be considered routine optimization by a skilled practitioner in the field.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,685 |
|---|---|
| Title | Treatment method and product for uterine fibroids using purified collagenase |
| Assignee(s) | Duke University, BioSpecifics Technologies LLC |